News

Study identifies molecular profile of rheumatoid arthritis patients with increased cardiovascular risk

07 Jun: Study identifies molecular profile of rheumatoid arthritis patients with increased cardiovascular risk

Editors’ notes This article has been reviewed according to Science X’s editorial process and policies. Editors have highlighted the following attributes while ensuring the content’s credibility: fact-checked peer-reviewed publication trusted source proofread by University of Córdoba Graphical abstract. Credit: Biomedicine & Pharmacotherapy (2024). DOI: 10.1016/j.biopha.2024.116357 Rheumatoid arthritis is an autoimmune disease of unknown origin that affects

Researchers report positive long-term results from study on chronic rhinitis treatment

07 Jun: Researchers report positive long-term results from study on chronic rhinitis treatment

Credit: Unsplash/CC0 Public Domain Neurent Medical, a company pioneering innovative non-surgical interventions to treat chronic inflammatory sinonasal diseases, today announced the publication of positive 12-month results from the CLARITY clinical trial in Laryngoscope Investigative Otolaryngology. This study demonstrates that treatment with Neurent Medical’s radiofrequency (RF) ablation device, the NEUROMARK system, is safe and resulted in

Teasing apart sex differences in heart disease

05 Jun: Teasing apart sex differences in heart disease

Credit: Pixabay/CC0 Public Domain Damian Di Florio, Ph.D., remembers the lightning-bolt moment five years ago when he began thinking differently about the questions scientists ask. He was a summer undergraduate student working in the lab of cardiovascular researcher DeLisa Fairweather, Ph.D., when she and another scientist gave a lecture about vitamin D. The lab’s studies

04 Jun: Controversy Grows as FDA Panel Prepares to Review MDMA Drug

A US Food and Drug Administration (FDA) expert panel will meet Tuesday to consider whether to recommend approval of an investigational midomafetamine (MDMA) capsule in combination with psychological intervention for the treatment of posttraumatic stress disorder (PTSD). But as the drug manufacturer, Lykos Therapeutics, inches closer to a final decision on its new drug application

23 May: Aficamten Advancing for Cardiomyopathy After SEQUOIA-HCM

LISBON, Portugal — A novel oral drug offers clinically meaningful improvements in exercise capacity in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM) and reduces the burden of limiting symptoms, new data from the SEQUOIA-HCM trial reveal. Aficamten is an investigational next-generation selective cardiac myosin inhibitor that reduces left ventricular contractility…